항진균제 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of antifungal drugs Market

The global antifungal drugs market size was valued at USD 17.83 billion in 2025. The market is projected to grow from USD 18.77 billion in 2026 to USD 28.35 billion by 2034, according to the report data provided. North America dominated the global market in 2025, supported by a high burden of fungal infections, advanced healthcare infrastructure, strong pharmaceutical research, and widespread availability of antifungal therapies.

Fungal infections range from superficial conditions affecting the skin, hair, and nails to severe systemic infections involving the lungs and other organs. Common conditions such as dermatophytosis, ringworm, athlete's foot, and fungal nail infections continue to generate demand for antifungal medicines. At the same time, serious infections such as candidiasis, aspergillosis, cryptococcosis, and mucormycosis are increasing the need for advanced therapeutic options.

Market Trends

Growing Use of Nanotechnology in Advanced Antifungal Formulations

The increasing prevalence of fungal diseases has encouraged pharmaceutical companies to develop improved drug-delivery systems. Nanotechnology is gaining attention for enhancing drug delivery, improving therapeutic effectiveness, and potentially addressing limitations associated with conventional antifungal formulations. Nanoemulsions and nanostructured delivery systems are being explored for conditions such as onychomycosis, oral candidiasis, and vaginal candidiasis. These developments are contributing to innovation within the antifungal drugs market.

Market Drivers

Rising Incidence of Hospital-Acquired Fungal Infections

The growing occurrence of healthcare-associated fungal infections is a major factor supporting market growth. Patients undergoing cancer treatment, transplantation, intensive care, or other procedures that weaken the immune system are particularly vulnerable to invasive fungal infections. Increasing hospital admissions and the rising population of immunocompromised patients are consequently generating sustained demand for antifungal medicines.

Expansion of Research and Development Activities

Pharmaceutical companies are increasing investments in research and clinical development to address treatment limitations, drug resistance, toxicity, and the growing complexity of invasive fungal infections. Existing therapies such as azoles, polyenes, and echinocandins remain important, while newer formulations and drug candidates are being developed to improve outcomes in difficult-to-treat infections.

Market Restraints

Adverse Effects Associated with Conventional Antifungal Drugs

Safety concerns associated with certain established antifungal medicines can restrict their use. Amphotericin B, for example, can be associated with adverse effects including nephrotoxicity, hypokalemia, and bone marrow suppression. In addition, increasing fungal resistance, availability of generic medicines, stringent regulatory requirements, patent expirations, and counterfeit products can create challenges for market expansion.

Segmentation Analysis

By Drug Type

The market is segmented into azoles, echinocandins, polyenes, and allylamines. Azoles represented the leading segment, supported by extensive clinical use and the availability of medicines such as fluconazole and ketoconazole. Echinocandins are also gaining importance because of their use in invasive systemic fungal infections. Polyenes remain important for serious infections, while allylamines are widely used for dermatological fungal conditions.

By Indication

The market is divided into dermatophytosis, aspergillosis, candidiasis, and others. Dermatophytosis held the leading position due to its widespread occurrence and high treatment demand. Candidiasis represents another important application because of the increasing incidence of healthcare-associated infections. Aspergillosis and other severe infections, including mucormycosis and fungal meningitis, are also supporting demand for advanced antifungal therapies.

By Route of Administration

The market includes oral, topical, and parenteral formulations. Topical antifungal medicines held a prominent position because of their extensive use for superficial skin and nail infections. Oral therapies are expected to experience strong demand as convenient treatment options become increasingly available, while parenteral formulations remain essential for severe and invasive fungal infections.

By Distribution Channel

Distribution channels include retail pharmacies, hospital pharmacies and stores, and online pharmacies. Hospital pharmacies represent an important channel because patients with severe fungal infections frequently require physician-supervised treatment. Retail pharmacies benefit from demand for dermatological antifungal products, while online pharmacies are gaining attention because of convenience and increasing consumer adoption of digital healthcare purchasing.

Regional Analysis

North America remained the leading regional market, valued at USD 4.61 billion in 2025. Strong healthcare infrastructure, awareness of fungal diseases, advanced treatment availability, and substantial pharmaceutical R&D activities support regional growth.

Europe held the second-largest position, supported by healthcare expenditure, established medical infrastructure, and increasing diagnosis and treatment of fungal infections.

Asia Pacific is expected to record the strongest growth during the forecast period. Rising healthcare investment, increasing fungal infection prevalence, expanding pharmaceutical activities, and government initiatives are creating significant market opportunities.

Latin America and the Middle East & Africa are expected to witness comparatively slower development, although improvements in healthcare access, disease awareness, and treatment availability could create future opportunities.

Key Industry Players

Prominent companies operating in the antifungal drugs market include Astellas Pharma Inc., Merck & Co., Inc., Pfizer Inc., Leadiant Biosciences, Inc., McKesson Medical-Surgical Inc., GlaxoSmithKline plc., Novartis AG, Bayer AG, and Abbott. These companies are focusing on product development, portfolio expansion, strategic collaborations, and clinical research to strengthen their market positions.

Investment Analysis and Opportunities

The market presents investment opportunities in novel antifungal therapies, advanced drug-delivery technologies, and treatments targeting resistant fungal infections. Companies developing formulations with improved safety, efficacy, patient convenience, and targeted delivery may benefit from increasing clinical demand. Asia Pacific also offers attractive opportunities because of expanding healthcare infrastructure and pharmaceutical manufacturing capabilities.

New Product Development

New product development is increasingly focused on overcoming the limitations of conventional antifungal medicines. Researchers are exploring nanoformulations, improved oral formulations, novel mechanisms of action, and therapies designed to address drug-resistant fungal pathogens. Such innovations can improve treatment outcomes while expanding therapeutic options for patients with severe infections.

Five Recent Developments

• April 2018: Sun Pharmaceutical Industries Ltd. launched Abzorb antifungal powder for dermatological fungal infections.
• October 2017: Mylan N.V. launched caspofungin acetate injection as a generic antifungal treatment.
• Pharmaceutical companies have continued expanding clinical research into novel therapies for invasive fungal infections.
• Drug-delivery technologies such as nanoemulsions are receiving greater attention for improving antifungal treatment.
• Strategic collaborations between pharmaceutical companies are supporting wider commercialization and regional availability of antifungal products.

Report Coverage

The antifungal drugs market report covers key market segments based on drug type, indication, route of administration, and distribution channel. It also evaluates regional market performance across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The report examines market trends, major drivers, restraints, competitive developments, product innovation, R&D activities, and emerging opportunities influencing the industry's development.

Conclusion

The global antifungal drugs market is positioned for steady expansion, increasing from USD 17.83 billion in 2025 to USD 18.77 billion in 2026 and reaching USD 28.35 billion by 2034. Rising fungal infection prevalence, hospital-acquired infections, pharmaceutical R&D, and advancements in drug-delivery technologies are expected to remain central to market development. While adverse effects, drug resistance, regulatory requirements, and treatment costs present challenges, innovation in novel formulations and therapies is creating significant opportunities for pharmaceutical companies across established and emerging markets.

Unit Value (USD billion)

Segmentation By Drug Type

• Azoles
• Echinocandins
• Polyenes
• Allylamines

By Indication

• Dermatophytosis
• Candidiasis
• Aspergillosis
• Others

By Route of Administration

• Oral
• Topical
• Parenteral

By Distribution Channel

• Hospitals & Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies

By Geography

• North America (the U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
• Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)
• Latin America (Brazil, Mexico, and the Rest of Latin America)
• Middle East & Africa (South Africa, GCC, and the Rest of Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Key Industry Developments (Mergers, Acquisitions, and Partnerships, etc.)
• 4.2. Prevalence of Fungal Infections
• 4.3. Pipeline Analysis
• 4.4. New Product Launches

5. Global Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Drug Type
  • 5.2.1. Azoles
  • 5.2.2. Echinocandins
  • 5.2.3. Polyenes
  • 5.2.4. Allylamines
• 5.3. Market Analysis, Insights and Forecast - By Indication
  • 5.3.1. Dermatophytosis
  • 5.3.2. Candidiasis
  • 5.3.3. Aspergillosis
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.4.1. Oral
  • 5.4.2. Topical
  • 5.4.3. Parenteral
• 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.5.1. Hospitals Pharmacies
  • 5.5.2. Retail Pharmacies & Drug Stores
  • 5.5.3. Online Pharmacies
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Drug Type
  • 6.2.1. Azoles
  • 6.2.2. Echinocandins
  • 6.2.3. Polyenes
  • 6.2.4. Allylamines
• 6.3. Market Analysis - By Indication
  • 6.3.1. Dermatophytosis
  • 6.3.2. Candidiasis
  • 6.3.3. Aspergillosis
  • 6.3.4. Others
• 6.4. Market Analysis - By Route of Administration
  • 6.4.1. Oral
  • 6.4.2. Topical
  • 6.4.3. Parenteral
• 6.5. Market Analysis - By Distribution Channel
  • 6.5.1. Hospitals Pharmacies
  • 6.5.2. Retail Pharmacies & Drug Stores
  • 6.5.3. Online Pharmacies
• 6.6. Market Analysis - By Country
  • 6.6.1. U.S.
  • 6.6.2. Canada

7. Europe Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Drug Type
  • 7.2.1. Azoles
  • 7.2.2. Echinocandins
  • 7.2.3. Polyenes
  • 7.2.4. Allylamines
• 7.3. Market Analysis - By Indication
  • 7.3.1. Dermatophytosis
  • 7.3.2. Candidiasis
  • 7.3.3. Aspergillosis
  • 7.3.4. Others
• 7.4. Market Analysis - By Route of Administration
  • 7.4.1. Oral
  • 7.4.2. Topical
  • 7.4.3. Parenteral
• 7.5. Market Analysis - By Distribution Channel
  • 7.5.1. Hospitals Pharmacies
  • 7.5.2. Retail Pharmacies & Drug Stores
  • 7.5.3. Online Pharmacies
• 7.6. Market Analysis - By Country/ sub-region
  • 7.6.1. U.K.
  • 7.6.2. Germany
  • 7.6.3. France
  • 7.6.4. Spain
  • 7.6.5. Italy
  • 7.6.6. Scandinavia
  • 7.6.7. Rest of Europe

8. Asia pacific Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Drug Type
  • 8.2.1. Azoles
  • 8.2.2. Echinocandins
  • 8.2.3. Polyenes
  • 8.2.4. Allylamines
• 8.3. Market Analysis - By Indication
  • 8.3.1. Dermatophytosis
  • 8.3.2. Candidiasis
  • 8.3.3. Aspergillosis
  • 8.3.4. Others
• 8.4. Market Analysis - By Route of Administration
  • 8.4.1. Oral
  • 8.4.2. Topical
  • 8.4.3. Parenteral
• 8.5. Market Analysis - By Distribution Channel
  • 8.5.1. Hospitals Pharmacies
  • 8.5.2. Retail Pharmacies & Drug Stores
  • 8.5.3. Online Pharmacies
• 8.6. Market Analysis - By Country/ sub-region
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. Australia
  • 8.6.5. Southeast Asia
  • 8.6.6. Rest of Asia Pacific

9. Latin America Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Drug Type
  • 9.2.1. Azoles
  • 9.2.2. Echinocandins
  • 9.2.3. Polyenes
  • 9.2.4. Allylamines
• 9.3. Market Analysis - By Indication
  • 9.3.1. Dermatophytosis
  • 9.3.2. Candidiasis
  • 9.3.3. Aspergillosis
  • 9.3.4. Others
• 9.4. Market Analysis - By Route of Administration
  • 9.4.1. Oral
  • 9.4.2. Topical
  • 9.4.3. Parenteral
• 9.5. Market Analysis - By Distribution Channel
  • 9.5.1. Hospitals Pharmacies
  • 9.5.2. Retail Pharmacies & Drug Stores
  • 9.5.3. Online Pharmacies
• 9.6. Market Analysis - By Country/ sub-region
  • 9.6.1. Brazil
  • 9.6.2. Mexico
  • 9.6.3. Rest of Latin America

10. Middle East & Africa Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis - By Drug Type
  • 10.2.1. Azoles
  • 10.2.2. Echinocandins
  • 10.2.3. Polyenes
  • 10.2.4. Allylamines
• 10.3. Market Analysis - By Indication
  • 10.3.1. Dermatophytosis
  • 10.3.2. Candidiasis
  • 10.3.3. Aspergillosis
  • 10.3.4. Others
• 10.4. Market Analysis - By Route of Administration
  • 10.4.1. Oral
  • 10.4.2. Topical
  • 10.4.3. Parenteral
• 10.5. Market Analysis - By Distribution Channel
  • 10.5.1. Hospitals Pharmacies
  • 10.5.2. Retail Pharmacies & Drug Stores
  • 10.5.3. Online Pharmacies
• 10.6. Market Analysis - By Country/ sub-region
  • 10.6.1. GCC Countries
  • 10.6.2. South Africa
  • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Competition Dashboard
• 11.4. Comparative Analysis - Major Players
• 11.5. Company Profiles
  • 11.5.1. Astellas Pharma Inc.
    • 11.5.1.1. Overview,
    • 11.5.1.2. Products & services,
    • 11.5.1.3. SWOT analysis,
    • 11.5.1.4. Recent developments,
    • 11.5.1.5. strategies,
    • 11.5.1.6. financials (based on availability)
  • 11.5.2. Merck & Co., Inc.
    • 11.5.2.1. Overview,
    • 11.5.2.2. Products & services,
    • 11.5.2.3. SWOT analysis,
    • 11.5.2.4. Recent developments,
    • 11.5.2.5. strategies,
    • 11.5.2.6. financials (based on availability)
  • 11.5.3. Pfizer Inc
    • 11.5.3.1. Overview,
    • 11.5.3.2. Products & services,
    • 11.5.3.3. SWOT analysis,
    • 11.5.3.4. Recent developments,
    • 11.5.3.5. strategies,
    • 11.5.3.6. financials (based on availability)
  • 11.5.4. Leadiant Biosciences, Inc.
    • 11.5.4.1. Overview,
    • 11.5.4.2. Products & services,
    • 11.5.4.3. SWOT analysis,
    • 11.5.4.4. Recent developments,
    • 11.5.4.5. strategies,
    • 11.5.4.6. financials (based on availability)
  • 11.5.5. McKesson Medical-Surgical Inc
    • 11.5.5.1. Overview,
    • 11.5.5.2. Products & services,
    • 11.5.5.3. SWOT analysis,
    • 11.5.5.4. Recent developments,
    • 11.5.5.5. strategies,
    • 11.5.5.6. financials (based on availability)
  • 11.5.6. GlaxoSmithKline plc.
    • 11.5.6.1. Overview,
    • 11.5.6.2. Products & services,
    • 11.5.6.3. SWOT analysis,
    • 11.5.6.4. Recent developments,
    • 11.5.6.5. strategies,
    • 11.5.6.6. financials (based on availability)
  • 11.5.7. Novartis AG
    • 11.5.7.1. Overview,
    • 11.5.7.2. Products & services,
    • 11.5.7.3. SWOT analysis,
    • 11.5.7.4. Recent developments,
    • 11.5.7.5. strategies,
    • 11.5.7.6. financials (based on availability)
  • 11.5.8. Bayer AG
    • 11.5.8.1. Overview,
    • 11.5.8.2. Products & services,
    • 11.5.8.3. SWOT analysis,
    • 11.5.8.4. Recent developments,
    • 11.5.8.5. strategies,
    • 11.5.8.6. financials (based on availability)
  • 11.5.9. Abbott
    • 11.5.9.1. Overview,
    • 11.5.9.2. Products & services,
    • 11.5.9.3. SWOT analysis,
    • 11.5.9.4. Recent developments,
    • 11.5.9.5. strategies,
    • 11.5.9.6. financials (based on availability)
  • 11.5.10. Other Prominent Players
    • 11.5.10.1. Overview,
    • 11.5.10.2. Products & services,
    • 11.5.10.3. SWOT analysis,
    • 11.5.10.4. Recent developments,
    • 11.5.10.5. strategies,
    • 11.5.10.6. financials (based on availability)

12. Strategic Recommendations